ABSTRACT
Background Congenital heart disease (CHD) is the commonest birth defect worldwide, affecting millions of newborns every year. Limited information is available regarding risk factors for its causation.
Objectives This study was planned with an aim to determine the viral etiology in infants with congenital heart disease. Although a number of viruses diseases have been etiologically linked to congenital defects, only two viruses namely rubella virus and cytomegalovirus are definitely proved to be associated with anomalies in infants.
Materials and Methods This Prospective study was conducted at a paediatric tertiary care hospital for a period of 6 months. Hundred (100) Infants with structural Congenital heart defects (CHD) based on Echocardiography findings were included in the study after taking informed consent from their mothers. Serum samples were collected and sent to Virology lab. The samples were tested for Rubella and Cytomegalovirus IgM antibodies using Enzyme Linked Immunosorbent Assay (ELISA).
Results Out of 100 infants with congenital heart defects, (M: F:56:44) 4% were seropositive for rubella IgM antibodies whereas 20% showed seropositivity of Cytomegalovirus IgM antibodies. Median age of infants was 25 days. The most common congenital heart defect in Rubella positive infants was Patent ductus arteriosus followed by Atrial septal defect whereas it was Patent ductus arteriosus only in CMV positive infants followed by Patent Foramen ovale. 6% of infants died and among them 50% had infection with CMV while 11% showed infection with Rubella.
Conclusion Regular screening by TORCH (Toxoplasmosis, Rubella, Cytomegalovirus, HSV) panel testing of mothers in first trimester is necessary for early detection. Early vaccination strategies should be implemented. Rapid and correct diagnosis of congenital CMV and Rubella infections in infants is very important for the correct therapy selection and proper management of the cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by DHR-ICMR,VRDL for procuring testing kits.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Present study is approved by the Institutional Ethics Committee, Osmania Medical College, Hyderabad, Telangana.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
